Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to
prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density
(BMD) in breast cancer patients with normal BMD. Investigators will compare the inhibitory
effects of denosumab on bone loss between participants with normal BMD to whom Letrozole or
Arimidex will be administered as postoperative endocrine therapy for stage I-IIIA
postmenopausal hormone-sensitive breast cancer and controls.